NasdaqGS - Nasdaq Real Time Price USD

Natera, Inc. (NTRA)

Time to buy NTRA?

152.97

-1.51

(-0.98%)

As of 12:46:29 PM EDT. Market Open.

Time to buy NTRA?

Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now

We recently compiled a list of the 13 Best Aggressive Growth Stocks to Buy Now. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against the other aggressive growth stocks. US stocks delivered a positive performance on Wednesday, April 23, after President Trump pointed out that he does […]

Insider Monkey 19 hours ago

NTRA
-0.98%
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

AUSTIN, Texas, April 24, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States.

Business Wire yesterday

NTRA
-0.98%
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

AUSTIN, Texas, April 22, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL.

Business Wire 2 days ago

NTRA
-0.98%
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Investor's Business Daily 7 days ago

EXAS

GH
+0.55%
NTRA
-0.98%
3 Top Stocks Estimated To Trade At Up To 48.4% Below Intrinsic Value

As the U.S. stock market navigates the complexities of trade tensions and regulatory changes, major indices like the Dow Jones and Nasdaq have experienced notable declines, particularly with technology stocks leading recent sell-offs. In this environment of uncertainty, identifying undervalued stocks becomes crucial for investors seeking potential opportunities, as these equities may offer value relative to their intrinsic worth despite prevailing market challenges.

Simply Wall St. 8 days ago

DDOG

NTRA
-0.98%
CPAY
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

StockStory 10 days ago

EXAS

NTRA
-0.98%
REGN
High Growth Tech Stocks In US With Potential For Expansion

The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.

Simply Wall St. 10 days ago

ALNY

ASND

NTRA
-0.98%
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

StockStory 11 days ago

REGN

NTRA
-0.98%
EXAS
Natera (NasdaqGS:NTRA) Climbs 11% in One Week

Natera (NasdaqGS:NTRA) experienced a 10.58% increase over the past week, following a set of recent developments. While there were no specific notable events directly influencing the company, the rise aligns with broader market trends, as the overall market climbed 5.4% in the same period. Given that earnings are expected to grow annually by 14%, investor sentiment may have been buoyed by positive market conditions. Without significant news from Natera, the price movement could largely mirror...

Simply Wall St. 12 days ago

NTRA
-0.98%
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?

We feel now is a pretty good time to analyse Natera, Inc.'s ( NASDAQ:NTRA ) business as it appears the company may be...

Simply Wall St. 14 days ago

NTRA
-0.98%
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love

We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against other stocks with buy ratings that hedge funds love. The U.S. stock market has been in chaos ever since President Trump announced his […]

Insider Monkey 17 days ago

NTRA
-0.98%
3 Reasons NTRA Has Explosive Upside Potential

Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over the past six months as its stock price is up 6.9% thanks to its solid quarterly results.

StockStory 17 days ago

NTRA
-0.98%
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks

Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. While Druckenmiller closed the firm in 2010, the George Soros protégé is still investing through his family office, the Duquesne Family Office, making him a great model for investors to follow. Roughly 27.5% of Druckenmiller's portfolio is invested in three under-the-radar artificial intelligence (AI) stocks.

Motley Fool 18 days ago

NTRA
-0.98%
COHR

CPNG
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry.

StockStory 18 days ago

INCY

EXAS

NTRA
-0.98%
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas, March 25, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Business Wire last month

NTRA
-0.98%
Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now?

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against the other best diagnostics stocks to invest in right now. Overview of the Clinical Diagnostics Market According to a report by Mordor […]

Insider Monkey last month

NTRA
-0.98%
Here’s What Lifted Natera (NTRA) in Q4 and 2024

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, the Fund (Investor Shares) returned 4.85% (net of fees) underperforming the Russell 1000 Growth Index’s 7.07% gain. For the year, the fund returned 26.85% compared […]

Insider Monkey last month

NTRA
-0.98%
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

StockStory last month

NTRA
-0.98%
EXAS

INCY
Is Natera (NTRA) the Best Biotech Stock According to Billionaires?

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against other biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could see […]

Insider Monkey last month

NTRA
-0.98%
Natera And 2 Other Stocks That May Be Trading Below Their Estimated Value

As the U.S. stock market experiences volatility with the S&P 500 and Nasdaq on track for their fourth consecutive week of losses, investors are keenly observing opportunities that may arise from these fluctuations. In this environment, identifying undervalued stocks becomes crucial as they offer potential value by trading below their estimated worth, providing a strategic entry point for those looking to capitalize on market corrections.

Simply Wall St. last month

NTRA
-0.98%
VRT

DY

Performance Overview

Return	NTRA	S&P 500 (^GSPC)
YTD	-3.37%	-6.44%
1-Year	+67.58%	+9.00%
3-Year	+285.61%	+28.09%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Natera, Inc. (NTRA)

Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

3 Top Stocks Estimated To Trade At Up To 48.4% Below Intrinsic Value

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

High Growth Tech Stocks In US With Potential For Expansion

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

Natera (NasdaqGS:NTRA) Climbs 11% in One Week

When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?

Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love

3 Reasons NTRA Has Explosive Upside Potential

27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now?

Here’s What Lifted Natera (NTRA) in Q4 and 2024

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Is Natera (NTRA) the Best Biotech Stock According to Billionaires?

Natera And 2 Other Stocks That May Be Trading Below Their Estimated Value

Performance Overview